1. Catalog
  2. 104: Fundamentals of Embolization
104: Fundamentals of Embolization
Create Account
Availability
On-Demand
Cost
Member: $0.00
Non-Member: $25.00
Patient: $0.00
Associate: $0.00
Student: $0.00
Early Career: $0.00
Industry Rep: $25.00
Credit Offered
1 AMA PRA Category 1 Credit
1 Participation Credit
  • Description
  • Learning Objectives
  • Accreditation Information
  • Faculty and Disclosures
  • Recommended
Although embolization is standard of care for some BCLC stages of HCC, hepatologists,
oncologists and general practitioners sometimes do not understand the ins and outs of
different techniques, when to refer, and the patient experience. There are many
resources detailing technique, but these are largely written for Interventional Radiology
audiences, and contain much more detail than other individuals caring for patients with
HCC need to know. The goal of this activity is to provide information specifically
targeted to hepatologists and others in the HCC care team about how embolization is
used. This will also help practitioners explain these aspects of care better to patients.
Upon completion of this session, participants should be able to:
  • Identify patient selection for transarterial embolization
  • Differentiate the difference between bland (TAE) and chemoembolization (TACE)
  • Describe the patient experience for trans arterial embolization techniques
The American Association for the Study of Liver Diseases is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association for the Study of Liver Diseases designates this enduring activity for a maximum of .5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This online educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence for Accredited Continuing Education by members of the AASLD Transplant Hepatology Board Review Course faculty, the AASLD Maintenance of Certification Committee and the AASLD Governing Board. As an accredited provider, AASLD must collect information from all planners, faculty and others in the planning and control of continuing medical education (CME) activities to disclose all of their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the education.

The American Association for the Study of Liver Diseases (AASLD) has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. Conflicts, if any, are resolved through one or more processes. All relevant conflicts pertaining to this activity have been mitigated.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings

Charles Kim, MD
Baylis Medical, ACI Humacyte, Kriya Therapeutics

Omobonike Oloruntoba-Sanders, MD
Nothing to Disclose

STAFF:

Steven Folstein, MFA, M Ed.
Nothing to Disclose

Wendy Risso, MPH
Nothing to Disclose

Sally Cook, CMP, CHCP
Nothing to Disclose

Powered By